Royal Bank Of Canada Coherus Bio Sciences, Inc. Transaction History

Royal Bank Of Canada

$528 Billion
Q2 2025

A detailed history of Royal Bank Of Canada transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 340,009 shares of CHRS stock, worth $465,812. This represents 0.0% of its overall portfolio holdings.

Number of Shares

340,009

Previous 5,738 5825.57%

Holding current value

$465,812

Previous $4,000 6100.0%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$0.72 - $1.12 $240,675 - $374,383	334,271 Added 5825.57%	340,009 $248,000
Q1 2025 May 15, 2025	SELL	$0.81 - $1.66 $4,318 - $8,849	-5,331 Reduced 48.16%	5,738 $4,000
Q4 2024 Feb 14, 2025	SELL	$0.67 - $1.71 $1,571 - $4,011	-2,346 Reduced 17.49%	11,069 $15,000
Q3 2024 Nov 14, 2024	BUY	$0.99 - $1.8 $3,031 - $5,511	3,062 Added 29.58%	13,415 $13,000
Q2 2024 Aug 14, 2024	BUY	$1.58 - $2.51 $9,026 - $14,339	5,713 Added 123.13%	10,353 $17,000
Q1 2024 Nov 05, 2024	SELL	$2.02 - $3.14 $11,540 - $17,938	-5,713 Reduced 55.18%	4,640 $11,000
Q1 2024 May 15, 2024	SELL	$2.02 - $3.14 $55,129 - $85,696	-27,292 Reduced 85.47%	4,640 $11,000
Q4 2023 Feb 14, 2024	SELL	$1.59 - $3.85 $8,039 - $19,465	-5,056 Reduced 13.67%	31,932 $106,000
Q3 2023 Nov 14, 2023	BUY	$3.74 - $5.45 $36,124 - $52,641	9,659 Added 35.34%	36,988 $138,000
Q2 2023 Aug 14, 2023	BUY	$3.79 - $8.3 $2,565 - $5,619	677 Added 2.54%	27,329 $116,000
Q1 2023 May 15, 2023	SELL	$5.89 - $10.52 $27,394 - $48,928	-4,651 Reduced 14.86%	26,652 $182,000
Q4 2022 Feb 14, 2023	BUY	$5.69 - $10.07 $9,752 - $17,259	1,714 Added 5.79%	31,303 $247,000
Q3 2022 Nov 14, 2022	SELL	$7.17 - $13.87 $72,682 - $140,600	-10,137 Reduced 25.52%	29,589 $285,000
Q2 2022 Aug 15, 2022	BUY	$5.86 - $13.23 $80,774 - $182,362	13,784 Added 53.13%	39,726 $287,000
Q1 2022 May 16, 2022	SELL	$10.92 - $16.41 $83,068 - $124,830	-7,607 Reduced 22.67%	25,942 $336,000
Q4 2021 Feb 14, 2022	BUY	$15.81 - $18.99 $128,487 - $154,331	8,127 Added 31.97%	33,549 $535,000
Q3 2021 Nov 15, 2021	SELL	$12.68 - $17.79 $149,624 - $209,922	-11,800 Reduced 31.7%	25,422 $408,000
Q2 2021 Aug 16, 2021	BUY	$12.95 - $15.41 $482,024 - $573,591	37,222 New	37,222 $516,000

Others Institutions Holding CHRS

# of Institutions

119

Shares Held

58.2M

Call Options Held

89.3K

Put Options Held

31K

View Full List

About Coherus BioSciences, Inc.

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $106M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

More about CHRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account

Royal Bank Of Canada Coherus Bio Sciences, Inc. Transaction History